Comprehensive medication guide to Ibsrela including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$75 copay with commercial insurance and the manufacturer copay program; prior authorization and step therapy typically required.
Estimated Cash Pricing
$2,000–$2,500 for a 30-day supply without insurance; eligible patients may pay as little as $0 with the Ibsrela Commercial Copay Program.
Medfinder Findability Score
60/100
Summarize with AI
On this page
Ibsrela (Tenapanor) is an FDA-approved prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) in adults. It belongs to a class of drugs called sodium/hydrogen exchanger 3 (NHE3) inhibitors. Ibsrela is the first and only NHE3 inhibitor approved for IBS-C, offering a unique mechanism of action compared to other treatments on the market.
The active ingredient, Tenapanor Hydrochloride, is also marketed under the brand name Xphozah for a separate indication (hyperphosphatemia in chronic kidney disease).
Ibsrela works by blocking the sodium/hydrogen exchanger 3 (NHE3) transporter located on the surface of intestinal cells. By inhibiting NHE3, Tenapanor reduces sodium absorption from the intestines, which increases fluid secretion into the intestinal lumen. This results in and associated with IBS-C.
![Why Is Ibsrela So Hard to Find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F1eaefb88f8e468c8195acc88197b8e9372f29af2-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
![How to Find a Doctor Who Can Prescribe Ibsrela Near You [2026 Guide]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F9192a2ca3d4ef8257e7cf94665702e309416d6c8-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Unlike some other IBS-C treatments, Ibsrela acts locally in the gut with minimal systemic absorption, which may contribute to its favorable side effect profile.
50 mg oral tablet — tablet
the only available strength. Taken twice daily, immediately before breakfast and dinner.
Ibsrela (Tenapanor) is a brand-name specialty medication manufactured solely by Ardelyx, Inc. While it is not currently listed on the FDA Drug Shortage Database, many local pharmacies do not routinely stock it due to its specialty status and high cost. Patients often need to use specialty pharmacies or order it through mail-order services. Medfinder can help you locate pharmacies that have Ibsrela in stock near you.
Ibsrela is most commonly prescribed by:
Telehealth consultations are also available for patients who need a prescription. If you're having trouble finding a prescriber, Medfinder can help connect you with providers in your area.
No, Ibsrela is not a controlled substance. It is not classified under any DEA schedule. This means there are no special prescribing restrictions related to controlled substance regulations, and refills can be obtained without additional DEA oversight.
The most commonly reported side effects of Ibsrela include:
Important warning: Ibsrela carries a boxed warning regarding the risk of serious dehydration in pediatric patients. It is contraindicated in children under 6 years of age and should be avoided in children 6 to 12 years old. If you experience severe diarrhea, rectal bleeding, or signs of dehydration, contact your healthcare provider immediately.
Know what you need? Skip the search.
Linzess (Linaclotide)
a guanylate cyclase-C agonist approved for IBS-C and chronic idiopathic constipation. Often the first-line treatment tried before Ibsrela.
Trulance (Plecanatide)
another guanylate cyclase-C agonist approved for IBS-C and chronic idiopathic constipation.
Amitiza (Lubiprostone)
a chloride channel activator used for IBS-C and chronic idiopathic constipation.
Motegrity (Prucalopride)
a 5-HT4 receptor agonist approved for chronic idiopathic constipation.
Prefer Ibsrela? We can find it.
OATP2B1 substrates (e.g., Enalapril)
moderateTenapanor inhibits the OATP2B1 transporter, which may reduce the absorption of co-administered OATP2B1 substrates. If taking Enalapril or similar medications, your doctor should monitor your blood pressure closely.
No significant CYP450 interactions
majorIbsrela does not inhibit major drug-metabolizing enzymes (P-gp, BCRP, OATP1B1, or OATP1B3).
Ibsrela offers a unique treatment option for adults with IBS-C through its first-in-class NHE3 inhibitor mechanism. While the medication is not currently in shortage, its specialty status and high retail cost ($2,000–$2,500 per month) can make it challenging to find at local pharmacies. The good news is that the manufacturer's copay program can bring out-of-pocket costs to as little as $0 for eligible patients with commercial insurance.
If you're struggling to find Ibsrela in stock, Medfinder can help you locate pharmacies near you that carry it. No generic version is currently available, with the earliest generic entry estimated for August 2033.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini